Skip to main content

Table 2 Protein expression of inflammatory factors in patients on day 1 and day 7

From: Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro

inflammatory meditors (pg/ml) Patient A Patient B
Day1 Day7 Day1 Day7
PDGF-AA/BB 417.63 2018.76 2390.86 1662.27
Eotaxin 19.05 83.34 41.54 22.47
MCP-1 15.3 345.62 45.36 28.24
MIP-1α 0.75 85.26 7.02 4.38
MIP-1β 52.65 343.41 250.35 227.16
GRO 103.05 716.22 467.43 536.83
CCL-5 4264.44 33,165.25 24,171.29 17,321.52
MCP-3 0.31 55.25 0.86 1.32
IL-6 1.32 53.78 7.28 1.45
IP-10 113.95 468.62 478.84 311.53
IL-1α 55.53 55.53 308.72 143.43